文献速递认知障碍与痴呆

预测淀粉样蛋白阳性的轻度认知障碍或轻度痴呆患者认知下降

Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia.
PubMed 文献 · Neurology · 2024-07-10

研究基于阿姆斯特丹痴呆队列961例淀粉样蛋白阳性患者,构建轻度认知障碍与轻度痴呆的MMSE预测模型,采用线性混合模型与立方时间曲线,内部交叉验证R2分别为0.15与0.26,可预测认知轨迹及达到特定MMSE的时间。

要点

  • 轻度认知障碍模型保留年龄、性别及脑脊液Aβ1-42和pTau作为时间变化效应。
  • 轻度痴呆模型保留Aβ1-42、年龄、APOE ε4及基线MMSE作为时间变化效应。
  • 模型可预测MMSE随时间变化及达到特定MMSE的时间,辅助个体化讨论。

核心结论

  • 构建了针对轻度认知障碍和轻度痴呆的模型,可预测MMSE随时间的变化,帮助患者了解潜在认知轨迹及剩余不确定性,并辅助个体化治疗效应的讨论。

研究设计与样本

  • 从阿姆斯特丹痴呆队列中选取淀粉样蛋白阳性且至少2次纵向MMSE测量的轻度认知障碍或轻度痴呆参与者。
  • 淀粉样蛋白阳性基于脑脊液AD生物标志物浓度或淀粉样蛋白PET。
  • 采用线性混合模型预测MMSE随时间变化,使用立方时间曲线及线性时间与基线预测因素的交互作用,并进行向后选择简化模型。
  • 轻度认知障碍与轻度痴呆分别建模,并进行内部5折交叉验证计算解释方差R2。

主要发现

  • 共纳入961例参与者,年龄65±7岁,49%女性;310例轻度认知障碍(MMSE 26±2),651例轻度痴呆(MMSE 22±4),随访2(四分位距1-4)年内有4±2次测量。
  • 轻度认知障碍和轻度痴呆的认知下降速率随时间增加(模型比较线性vs平方vs立方时间拟合,p<0.05支持立方拟合)。
  • 轻度认知障碍模型向后选择保留年龄、性别及脑脊液Aβ1-42和pTau浓度作为改变MMSE轨迹的时间变化效应。
  • 轻度痴呆模型保留的时间变化效应为Aβ1-42、年龄、APOE ε4及基线MMSE。
  • 内部交叉验证中,R2在轻度认知障碍模型为0.15,在轻度痴呆为0.26。

关键数值与推荐

  • 轻度认知障碍模型内部交叉验证R2=0.15。
  • 轻度痴呆模型内部交叉验证R2=0.26。
  • 假设患者基线MMSE 28、脑脊液Aβ1-42 925 pg/mL,预测6.0年(95% CI 5.4-6.7)后MMSE达20;假设治疗减少下降30%则为8.6年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cognitive decline rates in Alzheimer disease (AD) vary greatly. Disease-modifying treatments may alter cognitive decline trajectories, rendering their prediction increasingly relevant. We aimed to construct clinically applicable prediction models of cognitive decline in amyloid-positive patients with mild cognitive impairment (MCI) or mild dementia. METHODS: From the Amsterdam Dementia Cohort, we selected amyloid-positive participants with MCI or mild dementia and at least 2 longitudinal Mini-Mental State Examination (MMSE) measurements. Amyloid positivity was based on CSF AD biomarker concentrations or amyloid PET. We used linear mixed modeling to predict MMSE over time, describing trajectories using a cubic time curve and interactions between linear time and the baseline predictors age, sex, baseline MMSE, APOE ε4 dose, CSF β-amyloid (Aβ) 1-42 and pTau, and MRI total brain and hippocampal volume. Backward selection was used to reduce model complexity. These models can predict MMSE over follow-up or the time to an MMSE value. MCI and mild dementia were modeled separately. Internal 5-fold cross-validation was performed to calculate the explained variance (R2). RESULTS: In total, 961 participants were included (age 65 ± 7 years, 49% female), 310 had MCI (MMSE 26 ± 2) and 651 had mild dementia (MMSE 22 ± 4), with 4 ± 2 measurements over 2 (interquartile range 1-4) years. Cognitive decline rates increased over time for both MCI and mild dementia (model comparisons linear vs squared vs cubic time fit; p < 0.05 favoring a cubic fit). For MCI, backward selection retained age, sex, and CSF Aβ1-42 and pTau concentrations as time-varying effects altering the MMSE trajectory. For mild dementia, retained time-varying effects were Aβ1-42, age, APOE ε4, and baseline MMSE. R2 was 0.15 for the MCI model and 0.26 for mild dementia in internal cross-validation. A hypothetical patient with MCI, baseline MMSE 28, and CSF Aβ1-42 of 925 pg/mL was predicted to reach an MMSE of 20 after 6.0 years (95% CI 5.4-6.7) and after 8.6 years with a hypothetical treatment reducing decline by 30%. DISCUSSION: We constructed models for MCI and mild dementia that predict MMSE over time. These models could inform patients about their potential cognitive trajectory and the remaining uncertainty and aid in conversations about individualized potential treatment effects.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. van der Veere PJ, Hoogland J, Visser LNC, et al. Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia. Neurology. 2024. PMID: 38986053. doi:10.1212/WNL.0000000000209605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。